, Volume 5, Issue 2, pp 210–225

Protection against Parkinson’s disease progression: Clinical experience

Neuroprotective Approach

DOI: 10.1016/j.nurt.2008.01.007

Cite this article as:
LeWitt, P.A. & Taylor, D.C. Neurotherapeutics (2008) 5: 210. doi:10.1016/j.nurt.2008.01.007


Treatments with potential neuroprotective capability for Parkinson’s disease (PD) have been investigated in randomized, controlled, clinical trials and other studies since the mid-1980s. Although promising leads have arisen, no therapy has been proven to halt or slow disease progression. Several large-scale studies have highlighted progress in methodology, as well as the frustrations of translating laboratory science to practical applications. This review summarizes findings from clinical trials with several classes of compounds, including monoamine oxidase-B inhibitors (selegiline, lazabemide, rasagiline), dopaminergic drugs (ropinirole, pramipexole, levodopa), antioxidant strategies (α-tocopherol), mitochondrial energy enhancers (coenzyme Q10, creatine), antiapoptotic agents (TCH346, minocycline, CEP-1347), and antiglutamatergic compounds (riluzole). Beyond small-molecule pharmacology, gene therapy approaches, such as delivering neurotrophic substances (e.g., neurturin) by viral vector, are the next generation of treatment options.

Key Words

Parkinson’s diseaseneuroprotectionneurodegenerationclinical trialsdisease modification
Download to read the full article text

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2008

Authors and Affiliations

  1. 1.Department of NeurologyHenry Ford HospitalDetroit
  2. 2.Department of NeurologyWayne State University School of MedicineDetroit
  3. 3.Department of Neurology and OphthalmologyMichigan State University School of Osteopathic MedicineEast Lansing
  4. 4.Henry Ford Health Systems-Franklin Pointe Medical CenterSouthfield